CJC-1295 (without DAC) vs Nandrolone
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both CJC-1295 (without DAC) and Nandrolone can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
CJC-1295 (without DAC) Nandrolone
Weight 3,367.97 Da 274.40 Da (base)
Half-life 30 minutes - 2 hours ~6-12 days (decanoate)
Chain 30 amino acids —
Type GHRH analog 19-nortestosterone steroid (C18H26O2)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Nandrolone
01 Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
02 Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
03 Increased bone mineral density through direct osteoblast stimulation
04 Improved nitrogen retention and protein synthesis for accelerated recovery
05 Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
06 Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
07 Clinically demonstrated efficacy in treating anemia of chronic renal failure
08 Potential neuroprotective properties observed in preclinical research
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Nandrolone
100-200 mg/week (therapeutic) / 1x per week (decanoate) or 2-3x per week (NPP)
TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate)
Therapeutic - Anemia / Wasting 100-200 mg/week 1x per week (decanoate)
Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections
NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Nandrolone
Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
Water retention and bloating (less than testosterone at equianabolic doses)
Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
Increased appetite and weight gain
Mild acne and oily skin (less pronounced than testosterone)
Elevated hematocrit and hemoglobin (erythrocytosis)
Injection site pain or discomfort
Mild mood changes (some users report increased emotional sensitivity)
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
Nephrosis or the nephrotic phase of nephritis
Severe hepatic impairment
Hypercalcemia
Known hypersensitivity to nandrolone or any formulation components
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled heart failure or severe cardiovascular disease
Research Evidence
CJC-1295 (without DAC) Nandrolone
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest November 2024 April 2005
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.